Saturday, 2 April 2016

MORPHOTEK AND AREVA MED TO COLLABORATE ON LEAD-212 TARGETED ALPHA THERAPIES

EXTON, Pa. and COURBEVOIE, France, April 1 (Bernama-GLOBE NEWSWIRE) -- Morphotek®, Inc., a subsidiary of Eisai Inc., and AREVA Med, the AREVA Group medical subsidiary developing innovative therapies to fight cancer, announced today that they have entered into a collaborative project to assess the potential of a novel alpha radio-immunotherapy treatment in the fight against cancer.


No comments:

Post a Comment